Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Cancer Research

• Publication date

  2001-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 11489808
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extensive stage small cell lung cancer

  2001cited by this paper
• Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.

  2001cited by this paper
• A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)

  2000cited by this paper
• New chemotherapy agents for small cell lung cancer.

  2000cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.

  1999cited by this paper
• A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.

  1999cited by this paper
• Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.

  1999cited by this paper
• Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group.

  1999cited by this paper
• Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.

  1999cited by this paper
• Current management of small cell lung cancer.

  1997cited by this paper
• Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.

  1995influential reference
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

  1992cited by this paper
• Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper
• Bioavailability and pharmacokinetics of etoposide (VP-16).

  1985cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.

  2025cites this paper
• AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer

  2022cites this paper
• Green chemistry assisted synthesis of natural and synthetic compounds as anticancer agents

  2020cites this paper
• Regio- and stereoselective synthesis of dispirooxindole-pyrrolocarbazole hybrids via 1,3-dipolar cycloaddition reactions: Cytotoxic activity and SAR studies.

  2018cites this paper
• Synthesis of hetero annulated isoxazolo-, pyrido- and pyrimido carbazoles: Screened for in vitro antitumor activity and structure activity relationships, a novel 2-amino-4-(3'-bromo-4'-methoxyphenyl)-8-chloro-11H-pyrimido[4,5-a]carbazole as an antitumor agent.

  2017cites this paper
• Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence

  2014cites this paper
• Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer

  2014cites this paper
• Cu(OTf)2 catalyzed three component reaction: efficient synthesis of spiro[indoline-3,4'-pyrano[3,2-b]pyran derivatives and their anticancer potency towards A549 human lung cancer cell lines.

  2013cites this paper
• Chemotherapy for small cell lung cancer: a comprehensive review

  2012cites this paper
• Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study

  2010cites this paper
• A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596): A Trial of the Eastern Cooperative Oncology Group

  2009cites this paper
• Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.

  2007cites this paper
• Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.

  2006cites this paper
• In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.

  2006cites this paper
• Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.

  2006cites this paper
• Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914

  2006cites this paper
• A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer

  2006cites this paper
• The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy

  2005cites this paper
• Small-cell lung cancer: current therapy and novel agents.

  2005cites this paper
• Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Prognosis in Extensive Disease Small-Cell Lung Cancer

  2005cites this paper
• Recent advances in management of small-cell lung cancer.

  2004cites this paper
• Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer.

  2003cites this paper
• Topotecan as first-line therapy for small cell lung cancer.

  2003cites this paper
• The use of colony stimulating factors in elderly patients with cancer.

  2003cites this paper
• Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study.

  2003cites this paper
• Chemotherapy for small cell lung cancer.

  2003cites this paper
• Commentary on “Novel Doublets in Extensive-Stage Small-Cell Lung Cancer: A Randomized Phase II Study of Topotecan Plus Cisplatin or Paclitaxel (CALGB 9430)”

  2002cites this paper
• Role of small-molecule kit receptor tyrosine kinase inhibitors in the treatment of small-cell lung cancer.

  2002cites this paper